KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Revenue (2017 - 2025)

Historic Revenue for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $776.1 million.

  • Biomarin Pharmaceutical's Revenue rose 407.55% to $776.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 billion, marking a year-over-year increase of 1239.43%. This contributed to the annual value of $2.9 billion for FY2024, which is 1796.81% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Revenue of $776.1 million as of Q3 2025, which was up 407.55% from $825.4 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's Revenue's 5-year high stood at $825.4 million during Q2 2025, with a 5-year trough of $408.7 million in Q3 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's median Revenue value was $595.3 million (recorded in 2023), while the average stood at $608.5 million.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Revenue plummeted by 1427.1% in 2021 and then skyrocketed by 2828.19% in 2024.
  • Biomarin Pharmaceutical's Revenue (Quarter) stood at $449.8 million in 2021, then grew by 19.5% to $537.5 million in 2022, then rose by 20.22% to $646.2 million in 2023, then grew by 15.65% to $747.3 million in 2024, then rose by 3.86% to $776.1 million in 2025.
  • Its last three reported values are $776.1 million in Q3 2025, $825.4 million for Q2 2025, and $745.1 million during Q1 2025.